Shares of Edwards Lifesciences Corporation (NYSE:EW) have been assigned an average recommendation of “Buy” from the twenty-three brokerages that are currently covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $120.32.

A number of equities analysts have issued reports on the stock. Canaccord Genuity reaffirmed a “buy” rating and issued a $150.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Cowen and Company reaffirmed a “buy” rating and issued a $135.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Thursday, October 12th. BidaskClub cut shares of Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a research note on Friday, August 25th. Zacks Investment Research cut shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 17th. Finally, Bank of America Corporation raised their price objective on shares of Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, July 27th.

In other Edwards Lifesciences Corporation news, VP Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock in a transaction on Monday, October 16th. The shares were sold at an average price of $108.54, for a total value of $2,057,918.40. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Catherine M. Szyman sold 4,681 shares of Edwards Lifesciences Corporation stock in a transaction on Monday, July 31st. The shares were sold at an average price of $115.78, for a total transaction of $541,966.18. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 201,161 shares of company stock worth $22,826,072. 2.13% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of EW. BlackRock Inc. increased its stake in Edwards Lifesciences Corporation by 2,184.9% in the 1st quarter. BlackRock Inc. now owns 14,003,695 shares of the medical research company’s stock valued at $1,317,326,000 after buying an additional 13,390,818 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Edwards Lifesciences Corporation by 161.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock valued at $627,207,000 after buying an additional 3,277,726 shares during the last quarter. Egerton Capital UK LLP acquired a new stake in Edwards Lifesciences Corporation in the 2nd quarter valued at $217,805,000. Koch Industries Inc. increased its stake in Edwards Lifesciences Corporation by 28,363.1% in the 2nd quarter. Koch Industries Inc. now owns 1,397,254 shares of the medical research company’s stock valued at $1,386,000 after buying an additional 1,392,345 shares during the last quarter. Finally, Wedgewood Partners Inc. acquired a new stake in Edwards Lifesciences Corporation in the 1st quarter valued at $106,963,000. Hedge funds and other institutional investors own 81.90% of the company’s stock.

Edwards Lifesciences Corporation (EW) traded up 0.94% during midday trading on Friday, reaching $113.08. The company’s stock had a trading volume of 1,127,754 shares. The firm has a 50-day moving average price of $111.15 and a 200 day moving average price of $111.91. The stock has a market capitalization of $23.88 billion, a price-to-earnings ratio of 34.30 and a beta of 0.62. Edwards Lifesciences Corporation has a 52-week low of $81.12 and a 52-week high of $121.45.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.20. The business had revenue of $842.00 million during the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. Edwards Lifesciences Corporation’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.76 earnings per share. Equities research analysts predict that Edwards Lifesciences Corporation will post $3.78 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Edwards Lifesciences Corporation (EW) Given Average Rating of “Buy” by Brokerages” was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/22/edwards-lifesciences-corporation-ew-given-average-rating-of-buy-by-brokerages.html.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Analyst Recommendations for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.